Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)

Next Previous
Trial Profile

A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Arlocabtagene autoleucel (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms QUINTESSENTIAL
  • Sponsors Juno Therapeutics

Most Recent Events

  • 30 Jan 2025 Planned number of patients changed from 150 to 175.
  • 13 Jan 2025 Planned End Date changed from 4 Jun 2030 to 30 Jun 2032.
  • 13 Jan 2025 Planned primary completion date changed from 2 Oct 2026 to 30 Jun 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top